Hypertension is defined as high blood pressure or a long term medical condition in which the arterial blood pressure is continuously elevated. It is also explained as sustained diastolic BP more than 90mmHG accompanied by the elevated systolic BP more than 140mmHg. Diabetes mellitus is a disorder related with a wide variety of disorders in metabolism, the principal feature is hyperglycaemia caused by inadequate insulin action. Azilsartan and Telmisartan are widely used to control hypertension in diabetes patients. This dissertation was designed to assess the efficacy of Azilsartan and Telmisartan. Material and methods: Patients included in this study were diagnosed with Type 2 diabetes mellitus and Hypertension at least age of greater than or equal to 18yrs. Results: From 305 subjects with diabetes hypertensive patients included in the study, 152 patients received Azilsartan and 153 patients were prescribed with Telmisartan. Conclusion: Azilsartan 40mg and Telmisartan 40mg are proved to be efficacious in the patients with hypertension and T2DM, but Azilsartan 40mg has shown more efficacy than Telmisartan 40mg.
Diabetic neuropathy is a major long term problem allied with diabetes that can cause serious disability and also death. Fifty to seventy five percent of all ulcerations and non trauma amputations are a consequence of diabetic neuropathy. Epalrestat, duloxetine and epalrestat with methylcobalamine are widely used to overcome neuronal damage. This study was designed to evaluate the efficacy of these three drug regimens. Material and methods: Patients included in this study were experiencing pain because of diabetic neuropathy for more than 6 months but not more than 5 years. Results: From 236 subjects with diabetic neuropathy included in the study, 181 patients concluded final analysis. 55 patients dropped from the study (14, 23 and 18 patients from duloxetine, epalrestat+methylcobalamine combination and epalrestat respectively). Mean pain score was reduced from 5.01±1.99 (severe pain) at first visit to 2.86±2.10 (moderate pain) in the epalrestat group, from 6.41±1.73 (severe pain) at first visit to 2.38±1.58 (mild pain) in the duloxetine group and from 5.86±1.76 (severe pain) to 2.88±1.91 (mild pain) in the epalrestat with methylcobalamine group. Conclusion: We conclude that duloxetine was significantly more effective than epalrestat and epalrestat in combination with methylcobalamine in relieving diabetic neuropathic pain.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.